A micro-electroporation/electrophoresis-based vaccine screening system reveals the impact of vaccination orders on cross-protective immunity
简介:
- 作者: Yongyong Li, Jingshan Mo, Jing Liu, Ying Liang, Caiguanxi Deng, Zhangping Huang, Juan Jiang, Ming Liu, Xinmin Liu, Liru Shang, Xiafeng Wang, Xi Xie, Ji Wang
- 杂志: iScience
- Doi: https://www.doi.org/10.1016/j.isci.2023.108086
- 出版日期: 2023 Sep 27
论文中使用的产品/服务
Quotation shows PackGene:Human ACE2 overexpression stable HEK293T (hACE2-293T, PackGene Biotech) cells were cultured under an atmosphere of 5% CO2 at 37°C in Dulbecco’s modified Eagle’s medium (DMEM, #10-013-CVRC, Corining) supplemented with 10% inactivated FEB (#FSP500, ExCellBio), non-essential amino acids (NEAA, #11140-050, Gibco), 100 U/ml penicillin and 100 μg/ml streptomycin (#SV30010, HyClone).
Research Field:DNA Vaccine
Targeted organ:blood, liver
Animal or cell line strain:mouse
摘要
The constant emergence of mutated pathogens poses great challenges to the existing vaccine system. A screening system is needed to screen for antigen designs and vaccination strategies capable of inducing cross-protective immunity. Herein, we report a screening system based on DNA vaccines and a micro-electroporation/electrophoresis system (MEES), which greatly improved the efficacy of DNA vaccines, elevating humoral and cellular immune responses by over 400- and 35-fold respectively. Eighteen vaccination strategies were screened simultaneously by sequential immunization with vaccines derived from wildtype (WT) SARS-CoV-2, Delta, or Omicron BA.1 variant. Sequential vaccination of BA.1-WT-Delta vaccines with MEES induced potent neutralizing antibodies against all three viral strains and BA.5 variant, demonstrating that cross-protective immunity against future mutants can be successfully induced by existing strain-derived vaccines when a proper combination and order of sequential vaccination are used. Our screening system could be used for fast-seeking vaccination strategies for emerging pathogens in the future.
关于派真
作为一家专注于AAV 技术十余年，深耕基因治疗领域的CRO&CDMO，派真生物可提供从载体设计、构建到 AAV、慢病毒和 mRNA 服务的一站式解决方案。凭借深厚的技术实力、卓越的运营管理和高标准的服务交付，我们为全球客户提供一站式CMC解决方案，包括从早期概念验证、成药性评估到IIT、IND及BLA的各个阶段。
凭借我们独立知识产权的π-alphaTM 293 细胞AAV高产技术平台，我们能将AAV产量提高多至10倍，每批次产量可达1×10¹⁷vg，以满足多样化的商业化和临床项目需求。此外，我们定制化的mRNA和脂质纳米颗粒（LNP）产品及服务覆盖药物和疫苗开发的各个阶段，从研发到符合GMP的生产，提供端到端的一站式解决方案。
